시장보고서

상품코드

1800961

소화관 치료제 시장 보고서 : 유형별, 투여 경로별, 용도별, 유통 채널별, 지역별(2025-2033년)

Gastrointestinal Therapeutics Market Report by Type, Route of Administration, Application, Distribution Channel, and Region 2025-2033

발행일: 2025년 08월 | 리서치사:

IMARC | 페이지 정보: 영문 133 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 소화관 치료제 시장 규모는 2024년 485억 달러에 달했습니다. IMARC Group은 2033년에는 718억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 4.23%를 보일 것으로 전망하고 있습니다.

위장(GI) 증후군은 소화관 장기의 기능에 영향을 미치는 의학적 질환을 말합니다. 위, 췌장, 소장, 대장, 담낭, 간에 영향을 미치며, 보통 소화불량, 가슴앓이, 변비, 복부 팽만감이 특징입니다. 일반적으로 사용되는 소화관 치료제로는 제산제, 완하제, 지사제, 구토제, 항궤양제 등의 처방약과 일반의약품, 내시경 검사, 엑스레이 검사, 혈액학적 검사 등이 있습니다. 이러한 치료제는 장애를 발견하고 음식의 영양 흡수를 돕고, 소화를 개선하고, 소화기 계통의 물의 흐름을 조절하고, 위산을 최소화합니다.

염증성 장질환(IBD) 및 궤양성 대장염과 같은 GI 질환의 유병률 증가는 시장 성장을 가속하는 주요 요인 중 하나입니다. 생활습관의 변화와 건강에 해로운 식습관으로 인해 전 세계 환자들 사이에서 질병 재발 가능성이 높아지고 있습니다. 또한, 이러한 질병에 취약한 노년층 인구가 증가하고 있는 것도 시장 성장의 원동력이 되고 있습니다. 이 질환의 치료를 위한 혁신적인 바이오시밀러 및 세포치료제 개발 등 다양한 기술적 진보가 또 다른 성장 촉진요인으로 작용하고 있습니다. 이러한 생물학적 제제는 정맥 주사 또는 피하 주사로 투여되며, 표적 치료를 위해 개별화되어 있습니다. 대중의 건강 인식 증가, 광범위한 조사 개발 활동, 특히 신흥 경제국의 의료 인프라가 크게 개선되는 등 다른 요인들도 시장을 더욱 견인할 것으로 예측됩니다.

본 보고서에서 다룬 주요 질문

세계 소화기 치료제 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 성장할 것인가?
코로나19가 세계 소화기 치료제 시장에 미치는 영향은?
주요 지역 시장은?
유형별 시장 분석은?
투여경로별 시장 현황은?
용도별 시장 분석은?
유통 채널별 시장 현황은?
산업 가치사슬의 다양한 단계는?
업계의 주요 촉진요인과 과제는?
세계 소화기 치료제 시장 구조와 주요 기업은?
업계 내 경쟁은 어느 정도인가?

Gastrointestinal (GI) syndrome refers to a medical ailment that affects the functioning of organs in the digestive tract. It impacts the stomach, pancreas, small and large intestines, gall bladder and liver and is usually characterized by indigestion, heartburn, constipation and bloating. Some of the commonly used GI therapeutics include prescription and over-the-counter (OTC) drugs, such as antacids, laxatives, antidiarrheal agents, antiemetics, antiulcer agents, and endoscopic and radiological procedures and hematological tests. These therapeutics assist in the detection of the disorder and absorbing nutrients from the food to improve digestion, regulate water flow in the GI system and minimize gastric acidity.

The increasing prevalence of GI diseases, such as inflammatory bowel disease (IBD) and ulcerative colitis, is one of the key factors driving the growth of the market. Due to changing lifestyle patterns and unhealthy dietary habits, there is an increased probability of disease recurrence among patients across the globe. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Various technological advancements, such as the development of innovative biosimilars and cellular therapies for the treatment of the disorder, are acting as other growth-inducing factors. These biologics are administered through intravenous and subcutaneous injections and are personalized for targeted treatments. Other factors, including rising health consciousness among the masses, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, especially in developing economies, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Type:

Branded
Generic

Breakup by Route of Administration:

Oral
Intravenous
Others

Breakup by Application:

Ulcerative Colitis
Crohn's Disease
GERD
Others

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, GlaxoSmithKline Plc, Janssen Biotech Inc. (Johnson & Johnson), Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceuticals.

Key Questions Answered in This Report:

How has the global gastrointestinal therapeutics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global gastrointestinal therapeutics market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the application?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global gastrointestinal therapeutics market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Gastrointestinal Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Branded
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Generic
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Route of Administration

7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Intravenous
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by Application

8.1 Ulcerative Colitis
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Crohn's Disease
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 GERD
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 AbbVie Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 AstraZeneca Plc
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Bausch Health Companies Inc.
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Bayer Aktiengesellschaft
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 GlaxoSmithKline Plc
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Janssen Biotech Inc. (Johnson & Johnson)
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
- 15.3.8 Novo Nordisk A/S
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Pfizer Inc.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Takeda Pharmaceuticals
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis

소화관 치료제 시장 보고서 : 유형별, 투여 경로별, 용도별, 유통 채널별, 지역별(2025-2033년)

Gastrointestinal Therapeutics Market Report by Type, Route of Administration, Application, Distribution Channel, and Region 2025-2033

본 보고서에서 다룬 주요 질문

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 서론

제5장 세계의 소화관 치료제 시장

제6장 시장 분석 : 유형별

제7장 시장 분석 : 투여 경로별

제8장 시장 분석 : 용도별

제9장 시장 분석 : 유통 채널별

제10장 시장 분석 : 지역별

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter의 Five Forces 분석

제14장 가격 분석

제15장 경쟁 구도